Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3–8.

PubMed  PubMed Central  Google Scholar 

Anderson KE. Behavioral disturbances in parkinson’s disease. Dialogues Clin Neurosci. 2004;6(3):323–32.

PubMed  PubMed Central  Google Scholar 

Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21.

CAS  PubMed  PubMed Central  Google Scholar 

Willis AW, Roberts E, Beck JC, Fiske B, Ross W, Savica R, et al. Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 2022;8(1):170.

CAS  PubMed  PubMed Central  Google Scholar 

Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Albin RL, et al. Current and projected future economic burden of parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15.

PubMed  PubMed Central  Google Scholar 

Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–44.

CAS  PubMed  Google Scholar 

Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.

CAS  PubMed  Google Scholar 

Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of parkinson’s disease. Lancet. 2024;403(10423):293–304.

CAS  PubMed  Google Scholar 

Jiang P, Dickson DW. Parkinson’s disease: experimental models and reality. Acta Neuropathol. 2018;135(1):13–32.

CAS  PubMed  Google Scholar 

Dovonou A, Bolduc C, Soto Linan V, Gora C, Peralta Iii MR, Levesque M. Animal models of parkinson’s disease: bridging the gap between disease hallmarks and research questions. Transl Neurodegener. 2023;12(1):36.

PubMed  PubMed Central  Google Scholar 

Zeng XS, Geng WS, Jia JJ. Neurotoxin-Induced animal models of Parkinson disease: pathogenic mechanism and assessment. ASN Neuro. 2018;10:1759091418777438.

CAS  PubMed  PubMed Central  Google Scholar 

Blesa J, Przedborski S. Parkinson’s disease: animal models and dopaminergic cell vulnerability. Front Neuroanat. 2014;8:155.

PubMed  PubMed Central  Google Scholar 

Dutta G, Zhang P, Liu B. The lipopolysaccharide parkinson’s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol. 2008;22(5):453–64.

CAS  PubMed  PubMed Central  Google Scholar 

Liu M, Bing G. Lipopolysaccharide animal models for parkinson’s disease. Parkinsons Dis. 2011;2011:327089.

PubMed  PubMed Central  Google Scholar 

Sharma N, Kapoor M, Nehru B, Apocyanin. NADPH oxidase inhibitor prevents lipopolysaccharide induced alpha-synuclein aggregation and ameliorates motor function deficits in rats: possible role of biochemical and inflammatory alterations. Behav Brain Res. 2016;296:177–90.

CAS  PubMed  Google Scholar 

Genc S, Zadeoglulari Z, Fuss SH, Genc K. The adverse effects of air pollution on the nervous system. J Toxicol. 2012;2012:782462.

PubMed  PubMed Central  Google Scholar 

He Q, Yu W, Wu J, Chen C, Lou Z, Zhang Q, et al. Intranasal LPS-mediated parkinson’s model challenges the pathogenesis of nasal cavity and environmental toxins. PLoS ONE. 2013;8(11):e78418.

CAS  PubMed  PubMed Central  Google Scholar 

Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA, et al. Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res. 2009;87(8):1913–21.

CAS  PubMed  PubMed Central  Google Scholar 

Wang TA, Li SY, Fann LY, Li IH, Liu TT, Hung HY, et al. Neuroprotective potential of isofraxidin: alleviating parkinsonian symptoms, inflammation and microglial activation. J Cent Nerv Syst Dis. 2025;17:11795735241312661.

PubMed  PubMed Central  Google Scholar 

van der Haar Avila I, Windhouwer B, van Vliet SJ. Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment. Cancer Metastasis Rev. 2023;42(3):941–58.

PubMed  PubMed Central  Google Scholar 

Yu RK, Tsai YT, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides–an overview. J Oleo Sci. 2011;60(10):537–44.

CAS  PubMed  PubMed Central  Google Scholar 

Galleguillos D, Wang Q, Steinberg N, Zaidi A, Shrivastava G, Dhami K, et al. Anti-inflammatory role of GM1 and other gangliosides on microglia. J Neuroinflammation. 2022;19(1):9.

CAS  PubMed  PubMed Central  Google Scholar 

Schneider JS. A critical role for GM1 ganglioside in the pathophysiology and potential treatment of parkinson’s disease. Glycoconj J. 2022;39(1):13–26.

CAS  PubMed  Google Scholar 

Schneider JS. GM1 Ganglioside as a Disease-Modifying Therapeutic for Parkinson’s Disease: A Multi-Functional Glycosphingolipid That Targets Multiple Parkinson’s Disease-Relevant Pathogenic Mechanisms. Int J Mol Sci. 2023;24(11).

Inci OK, Basirli H, Can M, Yanbul S, Seyrantepe V. Gangliosides as therapeutic targets for neurodegenerative diseases. J Lipids. 2024;2024:4530255.

PubMed  PubMed Central  Google Scholar 

Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, et al. Elevated GM3 plasma concentration in idiopathic parkinson’s disease: A lipidomic analysis. PLoS ONE. 2017;12(2):e0172348.

PubMed  PubMed Central  Google Scholar 

Akiyama H, Ramirez NG, Gudheti MV, Gummuluru S. CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies. PLoS Pathog. 2015;11(3):e1004751.

PubMed  PubMed Central  Google Scholar 

Ding Y, Ma K, Tsui ZC. Induction of nitric oxide production by ganglioside GM3 in murine peritoneal macrophages activated for tumor cytotoxicity. Vivo. 1998;12(3):357–61.

CAS  Google Scholar 

Kanoh H, Nitta T, Go S, Inamori KI, Veillon L, Nihei W, et al. Homeostatic and pathogenic roles of GM3 ganglioside molecular species in TLR4 signaling in obesity. EMBO J. 2020;39(12):e101732.

CAS  PubMed  PubMed Central  Google Scholar 

Park J, Kwak CH, Ha SH, Kwon KM, Abekura F, Cho SH, et al. Ganglioside GM3 suppresses lipopolysaccharide-induced inflammatory responses in rAW 264.7 macrophage cells through NF-kappaB, AP-1, and MAPKs signaling. J Cell Biochem. 2018;119(1):1173–82.

CAS  PubMed  Google Scholar 

Inokuchi JI, Kanoh H, Inamori KI, Nagafuku M, Nitta T, Fukase K. Homeostatic and pathogenic roles of the GM3 ganglioside. FEBS J. 2022;289(17):5152–65.

CAS  PubMed  Google Scholar 

Matsuo S, Okamoto K. Enhancement of FK-506 activities by ganglioside (GM3) in vivo. Life Sci. 1995;57(13):PL165–9.

CAS  PubMed  Google Scholar 

Alsulimani HH, Ye Q, Kim J. Effect of hfe deficiency on memory capacity and motor coordination after manganese exposure by drinking water in mice. Toxicol Res. 2015;31(4):347–54.

CAS  PubMed  PubMed Central  Google Scholar 

Stanley JL, Lincoln RJ, Brown TA, McDonald LM, Dawson GR, Reynolds DS. The mouse beam walking assay offers improved sensitivity over the mouse Rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol. 2005;19(3):221–7.

CAS  PubMed  Google Scholar 

Park HS, Song YS, Moon BS, Yoo SE, Lee JM, Chung YT, et al. Neurorestorative effects of a novel Fas-Associated factor 1 inhibitor in the MPTP model: an [(18)F]FE-PE2I positron emission tomography analysis study. Front Pharmacol. 2020;11:953.

CAS  PubMed  PubMed Central  Google Scholar 

Arora P, Singh K, Kumari M, Trivedi R. Temporal profile of serum metabolites and inflammation following closed head injury in rats is associated with HPA axis hyperactivity. Metabolomics. 2022;18(5):28.

CAS  PubMed  Google Scholar 

Fernandez-Arjona MDM, Grondona JM, Granados-Duran P, Fernandez-Llebrez P, Lopez-Avalos MD. Microglia morphological categorization in a rat model of neuroinflammation by hierarchical cluster and principal components analysis. Front Cell Neurosci. 2017;11:235.

PubMed  PubMed Central